Chattem Icy Hot Patch Launch Expected To Drive Topical Analgesic Growth
This article was originally published in The Tan Sheet
Executive Summary
Chattem is projecting $3 mil. to $5 mil. in sales growth for its topical analgesics franchise in FY 2001, primarily driven by the launch of Icy Hot Patch, the firm told analysts during an earnings conference call Jan. 26.
You may also be interested in...
Dexatrim Natural Fattens Chattem's First Quarter; Extensions Planned
Sales of Chattem's Dexatrim line increased nearly 5% in the fiscal first quarter ended Feb. 28 compared to the year-ago period, despite the loss of the flagship phenylpropanolamine-containing products.
Dexatrim Natural Fattens Chattem's First Quarter; Extensions Planned
Sales of Chattem's Dexatrim line increased nearly 5% in the fiscal first quarter ended Feb. 28 compared to the year-ago period, despite the loss of the flagship phenylpropanolamine-containing products.
Dexatrim Natural Fattens Chattem's First Quarter; Extensions Planned
Sales of Chattem's Dexatrim line increased nearly 5% in the fiscal first quarter ended Feb. 28 compared to the year-ago period, despite the loss of the flagship phenylpropanolamine-containing products.